Drugs / ALTB-268
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07350577 | Nov 2025 → Sep 2026 overdue | ulcerative colitis | AltruBio Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05723692 | Jan → Oct 2023 | — | AltruBio Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06109441 | Dec 2023 → Mar 2026 overdue | ulcerative colitis | AltruBio Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALTB-268 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06109441 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody” NCT05723692 ↗ |
| Route | Subcutaneous | “subcutaneously administered ALTB-268” NCT05723692 ↗ |